LeaningRisk marker

Is ApoB a better measure of risk than standard LDL cholesterol?

ApoB (the number of atherogenic particles) predicts cardiovascular risk better than LDL-C, especially when the two are discordant.

Standard LDL-C measures the cholesterol carried inside LDL particles, not how many particles there are. When those two disagree (discordance), risk tends to track the particle count (ApoB), not the cholesterol number. This view is increasingly accepted - even by people on opposite sides of the LDL-causality debate - though guidelines still lead with LDL-C for cost and habit.

Limited evidence so far: This claim currently rests on only 1 assessment. It is early-corpus and should be read as provisional - see the methodology and coverage matrix for the planned additions.

Evidence balance

Supports: 1(100% weighted share)Challenges: 0(0% weighted share)

Segment widths are weighted by evidence strength (a meta-analysis counts for more than a case report), so they will not match the raw study counts shown above. This is deliberate: it stops a weak study from visually outweighing a strong one. The weighting is an editorial ordinal display scale, not a probability or a meta-analytic effect estimate. See the methodology for the tier weighting.

Mainstream steelman

ApoB counts one molecule per atherogenic particle, so it directly measures particle number rather than the variable cholesterol cargo each particle carries. In every dataset where LDL-C and ApoB (or LDL particle number) diverge, cardiovascular risk follows the particle count. Discordance is common in insulin resistance and high triglycerides, where particles become small and cholesterol-depleted, so LDL-C systematically understates true particle burden. Lipidologists such as Peter Attia argue ApoB should largely replace LDL-C as the treatment target precisely because it removes this blind spot.

Skeptic steelman

The marker debate is somewhat internal to the mainstream and does not, by itself, settle whether lowering particles in a metabolically healthy person helps. ApoB and LDL-C are usually highly correlated, so for most people the extra information is modest, and adding a test does not change outcomes unless acting on it does. Skeptics also note that ApoB, like LDL-C, can be high in the LMHR phenotype while plaque remains low - so a "better marker" of particle count is still only a risk marker, not proof of harm in that context.

Bottom line

Moderate confidence

ApoB is a genuinely better measure of atherogenic particle burden than LDL-C and is the more reliable number when the two disagree, particularly in insulin resistance. That makes it the better marker; it does not by itself resolve whether lowering it benefits a metabolically healthy person (see the treatment and phenotype claims).

This is a clearly-labelled editorial judgment, not a fact. It is written to survive its own skeptic steelman above.

What would change this conclusion

Large outcome data showing that, when LDL-C and ApoB are discordant, events actually track LDL-C rather than ApoB; or evidence that acting on ApoB rather than LDL-C does not change management or outcomes for most people.

The evidence (1)

Strongest evidence first. Each card traces to a study and a verbatim quote with a locator.

SupportsModerate tierCoronary event
Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events
Circulation, 2014 - Prospective Cohort
In a large prospective cohort, when LDL-C diverged from apoB / LDL particle number, coronary risk tracked the particle measures - direct support that apoB carries information LDL-C misses when the two disagree. Moderate rather than high because it is observational and women-only.
“For women with discordant LDL-related measures, coronary risk may be underestimated or overestimated when LDL-C alone is used.”
- Abstract (Conclusions)
Applicability: Healthy women (Women's Health Study); generalizability to men not established here.
- Observational; residual confounding possible.